疣贅(Warts)の治療薬パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Warts - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Warts Overview 8
Therapeutics Development 9
Pipeline Products for Warts – Overview 9
Pipeline Products for Warts – Comparative Analysis 10
Warts – Therapeutics under Development by Companies 11
Warts – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Warts – Products under Development by Companies 15
Warts – Companies Involved in Therapeutics Development 16
3M Drug Delivery Systems 16
Agilvax, Inc. 17
Anaconda Pharma 18
BioMAS Ltd. 19
Burke Pharmaceuticals, LLC 20
Cutanea Life Sciences 21
Foamix Pharmaceuticals Ltd. 22
G&E Herbal Biotechnology Co., Ltd. 23
Helix BioPharma Corp. 24
NanoViricides, Inc. 25
Nielsen Biosciences, Inc. 26
ViroStatics, srl 27
Warts – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(digoxin + furosemide) – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
854-A – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
A-101 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AP-611074 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AS-101 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AX-03 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BURKE-201 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Candida Albicans Antigen – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HerpeCide-I – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
imiquimod – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
interferon alpha-2b (recombinant) – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PP-210 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SRT-100 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Warts – Recent Pipeline Updates 54
Warts – Dormant Projects 57
Warts – Discontinued Products 58
Warts – Product Development Milestones 59
Featured News & Press Releases 59
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 59
Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 59
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 60
Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts 61
Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63


【レポート販売概要】

■ タイトル:疣贅(Warts)の治療薬パイプライン動向(2015年上半期版)
■ 英文:Warts - Pipeline Review, H1 2015
■ 発行日:2015年1月22日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6060IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。